Zenith Capital Corp. (ZHCLF)

Overview

Zenith Capital Corp. operates in the biotechnology investment sector, focusing on the discovery and development of novel therapeutic agents for oncology and other diseases with significant unmet medical needs. Originally established as Zenith Epigenetics Corp., the company underwent a name change to Zenith Capital Corp. in August 2016 to better reflect its widened scope and strategic direction. Since its incorporation in 2013, Zenith Capital Corp. has been dedicated to pushing the boundaries of medical science, particularly in the area of bromodomain inhibitors. Based in Calgary, Canada, Zenith Capital Corp. is at the forefront of developing cutting-edge treatments with the potential to dramatically improve patient outcomes in several hard-to-treat diseases.

Products and Services

• ZEN-3694:

  This lead compound represents the pinnacle of Zenith Capital Corp.'s research into bromodomain inhibitors. It is specifically designed for the treatment of cancers that are notoriously difficult to manage and for which current therapeutic options are either limited or ineffective. ZEN-3694 is currently undergoing Phase 2b clinical trials, targeting two such conditions:

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC): A challenging form of prostate cancer that no longer responds to hormonal therapies, making it particularly tough to treat. The development of ZEN-3694 for mCRPC symbolizes hope for patients who currently have few treatment options.
  • Metastatic Triple Negative Breast Cancer (mTNBC): This type of breast cancer lacks three commonly found receptors known to fuel most breast cancer growth—estrogen, progesterone, and the HER-2/neu gene—making it more difficult to treat with current therapies. The advancement of ZEN-3694 into Phase 2b clinical trials for mTNBC offers a promising new direction for treatment strategies in this subset of breast cancer patients.